News

Advicenne announces FDA clearance of IND to commence pivotal Phase 3 trial of ADV7103 for distal Renal Tubular Acidosis

Advicenne announces FDA clearance of IND to commence pivotal Phase 3 trial of ADV7103 for distal Renal Tubular Acidosis

Advicenne announces FDA clearance of IND to commence pivotal Phase 3 trial of ADV7103 for distal Renal Tubular Acidosis

Proteomedix raises 5.2 MCHF in financing round

Proteomedix raises 5.2 MCHF in financing round

ProteoMediX AG, a diagnostic company developing blood-based tests for the accurate diagnosis and prognosis of prostate cancer, has announced the successful closing of an equity financing round. The company raised CHF 5.2 million (€ 4.6 million) from existing investors.

NANOBIOTIX TO PRESENT POSITIVE RESULTS FROM ITS PHASE II/III CLINICAL TRIAL OF NBTXR3 IN PATIENTS WITH SOFT TISSUE SARCOMA (STS) AND OTHER ONGOING PHASE I/II TRIALS AT UPCOMING ESMO AND ASTRO ANNUAL CONFERENCES

NANOBIOTIX TO PRESENT POSITIVE RESULTS FROM ITS PHASE II/III CLINICAL TRIAL OF NBTXR3 IN PATIENTS WITH SOFT TISSUE SARCOMA (STS) AND OTHER ONGOING PHASE I/II TRIALS AT UPCOMING ESMO AND ASTRO ANNUAL CONFERENCES

Nanobiotix announced today that detailed results of its phase II/III clinical trial of NBTXR3 in patients with soft tissue sarcoma (STS) will be presented by Dr. Sylvie Bonvalot, MD, PhD at the ESMO 2018 Congress in Munich

Advicenne receives approval for Marketing Authorization for ADV6209 in Pediatric Moderate Sedation

Advicenne receives approval for Marketing Authorization for ADV6209 in Pediatric Moderate Sedation

Advicenne receives approval for Marketing Authorization for ADV6209 in Pediatric Moderate Sedation

DTAMedical lance son traitement des plaies aiguës sans contact

DTAMedical lance son traitement des plaies aiguës sans contact

Grâce à l’obtention du marquage CE pour son dispositif médical VistaCare One, annoncé ce mercredi, la société jurassienne va pouvoir commercialiser une première version auprès des hôpitaux dès ce deuxième trimestre.
NANOBIOTIX  ANNOUNCES POSITIVE PHASE II/III  TOPLINE DATA IN SOFT TISSUE SARCOMA WITH NBTXR3

NANOBIOTIX ANNOUNCES POSITIVE PHASE II/III TOPLINE DATA IN SOFT TISSUE SARCOMA WITH NBTXR3

Nanobiotix, a late clinical stage nanomedicine company pioneering new approaches in the treatment of cancer, announced today positive topline results of the Phase II/III act.in.sarc trial evaluating NBTXR3 in Soft Tissue Sarcoma.

Advicenne annonce la présentation d’un poster concernant ADV7103 au 55ème Congrès de l’Association Européenne Néphrologie- Dialyse et Transplantation (ERA-EDTA)

Advicenne annonce la présentation d’un poster concernant ADV7103 au 55ème Congrès de l’Association Européenne Néphrologie- Dialyse et Transplantation (ERA-EDTA)

Advicenne annonce la présentation des résultats d’une étude comparant ADV7103 au traitement de référence chez des patients atteints d’ATRd.

LallianSe is a unique ecosystem dedicated to life sciences companies and innovators. We strive to accelerate the development of products and services than can change the lives of patients. Join us in the Adventure!

Hôpital de la Salpêtrière

LallianSe LAB offices :
HEUYER Building, 3rd Floor, Hôpital de la Pitié Salpêtrière,
47-83 boulevard de l'hôpital, 75013 Paris, France

4 + 10 =